A 20 Lymphoma
Mostrando 13-24 de 214 artigos, teses e dissertações.
-
13. Outcomes in relapsed Hodgkin's lymphoma treated with autologous and allogeneic hematopoietic cell transplantation at the Pontificia Universidad Católica de Chile
Introduction: Hodgkin's lymphoma is a highly curable disease. Autologous and reduced intensity allogeneic hematopoietic cell transplantations are alternatives to treat relapsed patients. Here, we report on the results of one service using these procedures. Methods: All patients who underwent transplantations in our institution between 1996 and 2014 were ret
Rev. Bras. Hematol. Hemoter.. Publicado em: 2015-06
-
14. Thyroid function, autoimmunity and nodules in hematological malignancies
Objective Hematological malignancies encompass a large spectrum of disease entities whose treatment by chemo/radiotherapy could lead to thyroid complications. To the best of our knowledge, no study has simultaneously addressed thyroid function, autoimmunity and nodularity. Therefore, we decided to conduct one.Materials and methods We evaluated 82 Caucasian p
Arch. Endocrinol. Metab.. Publicado em: 2015-06
-
15. Salvaged single-unit cord blood transplantation for 26 patients with hematologic malignancies not in remission
Treatments for patients with hematologic malignancies not in remission are limited, but a few clinical studies have investigated the effects of salvaged unrelated cord blood transplantation (CBT). We retrospectively studied 19 patients with acute leukemia, 5 with myelodysplastic syndrome (MDS with refractory anemia with excess blasts [RAEB]), and 2 with non-
Braz J Med Biol Res. Publicado em: 27/03/2015
-
16. Diagnosing lymphoma in a setting with a high burden of infection: a pediatric case of Epstein-Barr virus-associated aggressive B-cell lymphoma with t(8;14) (q23;q32) and extensive necrosis mimicking tuberculosis
The association of lymphoma with necrotic granuloma can pose diagnostic challenges and delay treatment, especially in settings with a high burden of infection. In these settings, the timely use of cytogenetic and molecular methods is most relevant. Here, we report a case of B-cell lymphoma with t (8;14) in a 5-year-old male child. The lymphoma was associated
Rev. Soc. Bras. Med. Trop.. Publicado em: 2015-01
-
17. Clinical and economic aspects of the use of rituximab in non-Hodgkin's lymphoma
O Linfoma não-Hodgkin (LNH) consiste em um grupo de neoplasias envolvendo, principalmente, as células B e representa 90% de todos os linfomas. A terapia atual disponível é baseada em quimioterapia associada ao anticorpo monoclonal rituximabe (Mab Thera(r)), que tem como alvo a proteína CD20, presente em mais de 80% das células B maduras do LNH. Recente
Braz. J. Pharm. Sci.. Publicado em: 2014-09
-
18. Case for diagnosis
We report the case of a 81-year-old female patient who had a two-year history of violet-colored erythematous tumors on both legs. Histopathological and immunohistochemical examinations confirmed the diagnosis of primary cutaneous large B-cell lymphoma, leg type. This rare, cutaneous lymphoma affects predominantly elderly females. Clinically, patients present
An. Bras. Dermatol.. Publicado em: 2014-07
-
19. Time-to-treatment of diffuse large B-cell lymphoma in São Paulo
OBJECTIVE: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma, accounting for nearly 50% of the cases in the Hematology Department of the Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo and Instituto do Câncer do Estado de São Paulo. The treatment outcome is influenced by age, abnormal lactate dehyd
Clinics. Publicado em: 2014
-
20. Expression of immunohistochemical markers in patients with AIDS-related lymphoma
AIDS-related lymphomas (ARL) present high biological heterogeneity. For better characterization of this type of lymphoma, the objectives of the present study were to evaluate the expression of immunohistochemical markers of cell differentiation (CD10, Bcl-6, MUM-1) and determine cell origin profile according to Hans' classification of diffuse large B-cell ly
Brazilian Journal of Infectious Diseases. Publicado em: 2012-02
-
21. Pathophysiology and molecular aspects of diffuse large B-cell lymphoma
Diffuse large B-Cell lymphoma is the most common subtype of non-Hodgkin lymphoma in the West. In Brazil, it is the fifth cause of cancer, with more than 55,000 cases and 26,000 deaths per year. At Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP, diffuse large B-Cell lymphoma represents 49.7% of all non-Hodgkin lymphoma
Rev. Bras. Hematol. Hemoter.. Publicado em: 2012
-
22. Follicular lymphoma: treatment and prognostic factors
Follicular lymphoma is the second most frequent non-Hodgkin lymphoma accounting for about 10-20% of all lymphomas in western countries. The median age at diagnosis is 60 years old. The clinical presentation is usually characterized by asymptomatic peripheral adenopathy in cervical, axillary, inguinal and femoral regions. Treatment options for patients with n
Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2012
-
23. Avaliação in vitro da atividade antiproliferativa de extratos das plantas Jodina rhombifolia HooK et Arn. e Carapa guianensis Aubl sobre células HL-60, Linfoma Daudi e Fibroblastos NIH-3T3 / In vitro anti-proliferative activity of extracts from Jodina rhombifolia HooK &Arn. and Carapa guianensis Aubl. on HL-60 cells, Daudi lymphoma and NIH-3T3 fibroblasts
Introduction-The incidence of cancer increases annually and is considered one of the main causes of mortality worldwide. Sixty-percent of chemotherapics were obtained from natural sources. Objective - this study aimed to assess the antiproliferative activity of extracts from leaves of Jodina rhombifolia Hook. Et Arn. (methanolic and watery) and seeds of Cara
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 28/07/2011
-
24. Autologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma
BACKGROUND: Hodgkin's lymphoma has high rates of cure, but in 15% to 20% of general patients and between 35% and 40% of those in advanced stages, the disease will progress or will relapse after initial treatment. For this group, hematopoietic stem cell transplantation is considered one option of salvage therapy. OBJECTIVES: To evaluate a group of 106 patient
Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2011-02